Cost Distribution Analysis Related to the Use of Tyrisine-Kinase Inhibitors (Tki) and the Combination of Pemetrexed/Cisplatin in the Treatment of Non-Small Cell Lung Cancer (Nsclc) Locally Advanced or Metastatic in Presence of Epidermal Gro ...
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.248
https://www.valueinhealthjournal.com/article/S1098-3015(15)02324-4/fulltext
Title :
Cost Distribution Analysis Related to the Use of Tyrisine-Kinase Inhibitors (Tki) and the Combination of Pemetrexed/Cisplatin in the Treatment of Non-Small Cell Lung Cancer (Nsclc) Locally Advanced or Metastatic in Presence of Epidermal Gro ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)02324-4&doi=10.1016/j.jval.2015.09.248
First page :
A819
Section Title :
Research Podium Presentations - Session 1
Open access? :
No
Section Order :
2472